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Smooth muscle caldesmon i hibits actomyosin MgATPase in the absence of Ca "+ and is the key regulatory component 
of Ca 2+-regulated thin filaments. We now show that caldesmon can affect contractility as Well. Glycerinated skeletal mus- 
cle fibres were treated so as to produce substantial contractions without Ca z+ as an activator. Addition of caldesmon 
caused reductions in force in a concentration- and time-dependent manner. Peffusion with caldesmon concentrations for
< 5 min gave up to 48% reduction in isometric tension with a half-maximal effect at 1.5/an caldesmon. Perfusion with 
15 gM caldesmon for 30 min gave an irreversible t nsion drop. 
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1. INTRODUCTION 
The protein caldesmon is present in all 
vertebrate smooth muscles and has been shown to 
be exclusively located as a component  o f  the thin 
f i laments o f  the contract i le apparatus  [1]. 
Ca ldesmon is a potent inhibi tor  of  actin act ivat ion 
o f  myosin  MgATPase  and it has been proposed 
that it is involved in the contro l  o f  contract i l i ty 
[2,3]. 
Ca 2+ controls smooth muscle contract i l i ty and in 
the test tube Ca 2+ controls the ATPase  activity o f  
the contract i le proteins,  actomyosin,  via 
regulatory mechanisms located both on the thick 
f i laments (Ca2+/calmodul in-dependent  myosin 
phosphory lat ion)  and the thin f i laments [4]. 
Whi lst  there is considerable vidence l inking 
myosin phosphory lat ion  with both act ivat ion of  
actomyos in  MgATPase  and init iat ion o f  contrac-  
t ion [5] we have less understanding o f  the role of  
ca ldesmon.  Recent work using ant i -ca ldesmon an- 
t ibody  has conf i rmed that ca ldesmon is essential in 
the Ca 2+ control  o f  thin f i lament act ivat ion o f  
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myosin MgATPase  [6]; in this study we have asked 
whether ca ldesmon can regulate muscle contracti l i -  
ty as well. In order to obtain an unambiguous 
answer we have developed a muscle preparat ion 
whose own intrinsic regulatory mechanisms are in- 
act ivated. This was done by desensitising 
glycer inated rabbit  psoas muscle fibres so that they 
contract  independent ly o f  Ca 2+. This contracti le 
model  provided a suitable system in which to in- 
vestigate the regulatory functions of  exogenous 
caldesmon.  
2. MATERIALS  AND METHODS 
Caldesmon was prepared by heat reatment of a sheep aorta 
homogenate according to [7]. Caldesmon was purified from the 
heat stable supcrnatant by the pH 3/35-500/0 (NI-h)2SO4 pro- 
cedure described in [2]. Yield was 0.25 mg protein/g artery. 
Smooth muscle actin and tropomyosin were prepared as in [8], 
and skeletal myosin as in [9]. All caldesmon preparations were 
tested for their ability to inhibit actin-tropomyosin activation of 
myosin MgATPase as described in [3]. 0.12 tool caldesmon per 
actin inhibited ATPase by 80 + 4o70 (n = 11). All statistical 
values quoted are mean + standard eviation. 
Rabbit psoas fibres were chemically skinned according to 
Eastwood et al. [10]. For mechanical measurements 4-6 fibres 
of 10 mm in length were mounted between atension transducer 
(Gould/Statham UC2) and a length drive coupled to a length 
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sensor [11]. The mounted fibres were immersed in a 
temperature-controlled continuous flow chamber and perfused 
with rigor buffer (5 mM EGTA, 5 mM MgClz, 50 mM KCI, 
1.5 mM NAN3, 1 mM dithiothreitol) at 1 ml/min. Maximal 
contractions were produced in 'Ca solution' (rigor + 4 mM 
MgATP + 4 mM CaCI2 (pCa 2+ 6.0)) and relaxation i 'EGTA' 
solution (rigor + 4 mM MgATP (pCa 2+ 9)). 
Desensitisation was based on Meinrenken's method [12]. The 
mounted muscle fibres were perfused with 50 mM KC1, 20 mM 
Tris (pH 8.0-8.1) at 39°C for 30 min at zero tension and then 
returned to rigor buffer at 25°C. 
3. RESULTS 
3.1. Desensitisation of  rabbit psoas muscle fibres 
The chemical ly skinned muscle fibres adjusted 
to zero tension in r igor buffer  produced contrac-  
t ions of  512/~N. fibre -~ + 4.9 (n = 21) in Ca solu- 
t ion. Fibres relaxed in EGTA solut ion to a steady 
force 15 _ 407o (n = 21) of  the maximal  contracti le 
force. Af ter  desensit isation treatment the maximal  
force in Ca solut ion was 342/~N. fibre -1 + 6 (n = 
19) whilst in EGTA solut ion the force was 68 _+ 
11070 (n = 17) of  maximal  force (see f ig. la) .  Desen- 
sitised fibres thus produced substantial  force in the 
absence of  Ca 2÷ and they remained desensitised 
dur ing many contract ions.  SDS-gel electrophoresis 
of  desensitised fibres showed that the protein com- 
ponents had not changed substantial ly;  in par-  
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Fig. 1. (a) Contraction of desensitised skeletal muscle fibres. 6 
psoas fibres were bathed in rigor solution at resting length 
having been treated with Meinrenken solution as described in 
section 2. Perfusion with EGTA solution gave an isometric 
contraction 68% of that obtained in Ca solution. Return to 
EGTA solution relaxed the muscle to a holding tension 76% of 
that in Ca solution. (b) Inhibition of isometric force by 
caldesmon. 6 desensitised psoas fibres were maximally activated 
in Ca solution. Perfusion with EGTA solution resulted in 71% 
of isometric force being produced without Ca z+. Addition of 
4/~M caldesmon reduced this tension in EGTA solution by 34% 
in 4.5 min. This tension drop was partly reversed by return to 
EGTA solution and maximum force was regained upon return 
to Ca solution. 
t icular t ropomyos in  and the t roponin  components 
were all still present. 
3.2. Effect of  caidesmon on isometric force 
When caldesmon (4/~M) was added to desen- 
sitised fibres in Ca solut ion there was no change in 
the isometric force (two preparat ions),  however, 
ca ldesmon did reduce the force product ion in 
EGTA solut ion ( f ig. lb) .  The reduct ion in force 
due to 4/~M caldesmon was 24 + 5070 (n = 9) [13]; 
with short incubations this inhibit ion was part ly 
reversed by washing in EGTA solut ion and fully 
reversed by a cycle of  EGTA,  Ca, EGTA solu- 
t ions. Brief sequential perfusion with increasing 
ca ldesmon concentrat ions showed its inhibitory ac- 
t ion to be concentrat ion dependent with a maximal  
inhibit ion of  force of  39-48070 and an average half- 
maximal  inhibit ion of  1.5/~M caldesmon _+ 0.4 
(n = 3). 
More  pro longed incubat ion with any one 
caldesmon concentrat ion in EGTA solut ion 
resulted in further reduct ion of  the force. For  ex- 
ample,  in one preparat ion the drops in tension due 
to 15/zM caldesmon at 1, 2, 5, 10, 15 and 19 min 
were 16.5, 20.2, 28.3, 35.1, 36.4 and 39.8070, 
respectively. F ig.2 shows that the tension drop 
fol lowing lengthy incubat ions in caldesmon 
became completely irreversible, even after washing 
in EGTA,  Ca, and EGTA solutions. The reduced 
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Fig.2. Irreversible drop in tension with increased time of 
exposure to 15/~M caldesmon. This was a continuous 
experiment involving a bundle of five desensitised psoas fibres. 
The inhibition of isometric force caused by caldesmon became 
progressively ess reversible with increased time of perfusion. 
After a total of 35 min in 15/~M caldesmon the tension drop 
was irreversible. 
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in caldesmon was not due to deterioration of the 
muscle since the maximal force in Ca solution did 
not change (fig.2). SDS-gel electrophoresis and im- 
munoblots of the fibres showed that in these condi- 
tions caldesmon was bound within the fibres at an 
estimated concentration of 20-50/zM (compare 
with 750/~M actin) and could not be removed even 
after extensive washes in EGTA or Ca solutions. 
3.3. Effects of  caldesmon on tension transients 
We imposed a rapid shortening of 12/zm 
(0.2-0.3070) and then held the muscle at constant 
length for 20 s before slowly stretching it back to 
its initial length. We recorded tension immediately 
following the release (T1) and after 20 s (T2) and 
calculated relative muscle stiffness [(T1 - To)/To] 
and force recovery [ (T2-  T1)/To]. Relative stiff- 
ness did not change significantly following the ad- 
dition of caldesmon (paired t-test; p > 0.1, n = 6) 
but 15/~M caldesmon markedly reduced 
[ (T2-  T1)/To] in every instance with an average 
reduction of 25.5070. This reduced amplitude of 
force recovery did not appear to be due to a change 
in the rate of tension recovery. 
4. DISCUSSION 
4.1. Desensitisation of  skeletal muscle fibres 
We have developed a novel method for desen- 
sitising glycerinated vertebrate skeletal muscle such 
that substantial isometric ontractions can be ob- 
tained in the absence of Ca 2+ (fig.la). 
The preparation has an advantage over the low 
salt/high pH method [14] which produces muscles 
incapable of generating significant tension with or 
without Ca 2+, or Mg-free treatment at low 
temperature where desensitisation is lost as soon as 
the fibres are returned to high Mg contracting solu- 
tions [11]. Desensitisation did not involve extensive 
removal of the regulatory proteins from the fibres 
and yet the preparations remained esensitised in
our buffer solutions indefinitely. This contractile 
model, whose own regulatory system is inac- 
tivated, provides an ideal system for investigating 
the regulatory functions of exogenous proteins. 
4.2. Caldesmon inhibition of  contraction 
Caldesmon is present in smooth muscle thin 
filaments where it is the inhibitory component of 
the Ca2+-dependent system which regulates thin 
filament activation of myosin MgATPase. It is an 
effective inhibitor with both skeletal and smooth 
muscle actins and myosins [2,3,15] and it also in- 
hibits the MgATPase activity of skeletal muscle 
desensitised myofibrils (not shown). The work 
reported in this paper shows, in addition, that it 
can inhibit muscle isometric ontraction thus con- 
firming that caldesmon's inhibition of MgATPase 
is related to its inhibition of force production. 
For short perfusions a half-maximal reduction 
in force was observed with 1.5/zM caldesmon 
which compares with a dissociation constant of 
0.3/zM for caldesmon binding to pure actin- 
tropomyosin. Prolonged incubation with high con- 
centrations resulted in irreversible loss of tension 
accompanied by irreversible binding of an 
estimated 20-50/~M caldesmon within the fibre in 
agreement with Galazkiewicz et al. [16]. 
Caldesmon did not affect relative muscle stiff- 
ness but at the highest concentration available, 
15/~M, it did reduce the extent of recovery of ten- 
sion following a quick release. This may be a 
reflection of the ability of caldesmon to increase 
skeletal or smooth heavy meromyosin binding to 
actin-tropomyosin in the presence of MgATP [17], 
an interaction which may be important in the for- 
mation of latch bridges [5] in smooth muscle. 
Other lines of research ave recently indicated 
that caldesmon can control contractility or motility 
[18-20] in agreement with our direct evidence. On 
this basis the caldesmon present in smooth muscle 
would be expected to play a role in regulating con- 
tractility in vivo. We hope to be able to extend our 
studies from this simple model system to the great- 
ly more complex intact smooth muscle system in 
the future. 
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